Synbio has signed a Master Services Agreement with a leading Australian clinical research organization, CRO Services Pty Ltd, a wholly owned subsidiary of ASX-listed Resonance Health Ltd (ASX: RHT). Under the agreement, Resonance will conduct a proof-of-concept clinical trial to assess the efficacy of FacialDx Incorporated (FacialDx) NIMSTM (Non-invasive Medical Screening) technology and evaluate its performance in real-world clinical conditions. Facial DX NIMSTM is a proactive, non-invasive AI-powered ...